

NCHIV 2019 – background information for accreditation

Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention & Treatment

13 November 2019, KIT, Amsterdam

**Oral abstracts will be selected by an extensive review committee consisting of experts from the fields of HIV pathogenesis, epidemiology, prevention and treatment. The committee will select the abstracts for oral presentation based on scientific merit and relevance to the field; contributions from young researchers are particularly encouraged.*

Session 1: Prevention (exact title to be confirmed)

Chairs: To be confirmed.

Combination HIV prevention from the global north to the global south

Prof. Waafa El Sadr (Columbia University, New York, USA)

3 selected oral abstracts relating to the subject of prevention of HIV/AIDS*

Prof. El-Sadr is professor of Epidemiology and Medicine at Columbia University, and director/founder of ICAP at Columbia University. In this role, she leads the design, implementation and evaluation of large-scale HIV programmes in sub-Saharan Africa and Asia that provide access to HIV services to more than 2.2 million people. Prof El-Sadr is a prominent researcher and has led numerous studies that have furthered the understanding of the prevention and management of HIV, tuberculosis and non-communicable diseases. She is also principal investigator of the NIH-funded HIV prevention Trials Network, which seeks to prevent HIV transmission globally.

At NCHIV 2019, Prof. El-Sadr will give an overview of different HIV prevention strategies in place today, taking lessons from, for example, New York city, as well as drawing on her broader experience throughout the world. Her talk will also include her perspectives on issues such as (assisted) self-testing, PrEP, and the vaginal ring. The presentation will provide NCHIV delegates with a comprehensive overview of the range of prevention projects currently underway, and will bring delegates up to date with the latest developments. It will therefore be of interest to all those who are involved in HIV prevention, ranging from clinicians and public health workers to members of the community.

This will be followed by a selection of oral abstract presentations on various aspects of HIV prevention.

Session 2: Epidemiology (exact title to be confirmed)

Chairs: To be confirmed.

The HIV epidemic in the Netherlands: an update

Peter Reiss (Stichting HIV Monitoring; AIGHD; AMC-UvA)

Challenges and needs for women living with HIV: From conception to infancy

Dr. Karoline Aebi-Popp (University Hospital Bern, Switzerland)

3 selected oral abstracts relating to the subject of epidemiology of HIV/AIDS*

Prof. Peter Reiss and colleagues from Stichting HIV Monitoring, will provide the conference participants with an update on the HIV epidemic in the Netherlands, based on the latest Monitoring Report published by Stichting HIV Monitoring.

Dr Aebi-Popp is a consultant obstetrician/gynaecologist, working as researcher in the Department of Infectious Diseases at the University Hospital Bern, Switzerland. Dr. Aebi-Popp has been actively involved in the design and implementation of many clinical studies in the field of HIV and women in collaboration with the Swiss HIV Cohort Study (SHCS) and the European Collaborative Study; the most important topics include pregnancy guidelines across Europe, mode of delivery, mother to child transmission with HSV2 co-infection and retention in care. Her current research interests involves topics around breastfeeding in HIV-positive women.

Dr Aebi-Popp will give a broad talk at NCHIV 2019, incorporating current issues such as breastfeeding in the U=U era, but also the use of dolutegravir during conception, global PMTCT progress and remaining challenges. This talk will be highly relevant to a wide range of conference participants, but will be of particular interest to those professionals who work closely with women and young children living with HIV.

The oral abstracts during this session will focus on various aspects of HIV epidemiology.

Session 3: Pathogenesis (exact title to be confirmed)

Chairs: To be confirmed.

[title to be confirmed]

Keynote: Dr. Anthony Fauci (NIH/NIAID, Bethesda, USA)

3 selected oral abstracts relating to the subject of HIV pathogenesis*

The prevention session will open with a keynote lecture by Dr Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID). At the NIAID, Dr Fauci oversees an extensive portfolio of basic and applied research to prevent, diagnose, and treat established infectious diseases, including HIV/AIDS. Dr. Fauci has made seminal contributions to the understanding of how HIV destroys the body's defenses leading to its susceptibility to deadly infections. Further, he has been instrumental in developing treatments that enable people with HIV to live long and active lives. He continues to devote much of his research to the immunopathogenic mechanisms of HIV infection and the scope of the body's immune responses to HIV.

Drawing on his extensive experience and expertise, at NCHIV 2019 Dr Fauci will give an update on the progress towards HIV cure and vaccine development. The talk will be accessible to a wide audience, ranging from basic science researchers through to HIV clinicians and nurse consultants.

This will be followed by a selection of oral abstract presentations on various aspects of HIV pathogenesis.

Session 4: Treatment (exact title to be confirmed)

Chairs: To be confirmed

ART: a changing landscape

Prof. Chloe Orkin (Barts Health NHS Trust, London, UK)

3 selected oral abstracts relating to the subject of HIV treatment*

Professor Chloe Orkin is Chair of the British HIV Association and Consultant Physician at the Royal London Hospital where her clinical duties include running an HIV and HIV/ HCV research unit. Her specialist interests are: Antiretroviral therapy, hepatitis and oncology. She has co-authored four British HIV Association guidelines on: Anti-retroviral therapy, Hepatitis, Malignancy and Routine Monitoring. Prof. Orkin is actively researching ways of implementing HIV and blood-borne virus testing.

In her talk at NCHIV 2019, Prof. Orkin will discuss the current antiretroviral therapy landscape, focusing on relevant issues such as the positioning of older and new drugs, long-acting ARVs, the challenges of switching, and special populations. This talk will bring all those involved in both HIV treatment and prevention up to date with the latest developments in antiretroviral therapy.

Selected oral abstract presentations will cover a range of issues relating to treatment of HIV.